UNSPSC 51373203: Dioxaphetyl butyrate

This classification denotes an opioid receptor agonist and opioid and analgesic agent with the molecular formula C22H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G751H98FY4, chemically known as 4-morpholinebutyric acid, alpha,alpha-diphenyl-, ethyl ester but more generally known as dioxaphetyl butyrate, which bears US NIH Compound Identifier 48194. European Medicines Agency schedules Dioxaphetyl butyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07202MIG.

UNSPSC 51373203 Dioxaphetyl butyrate is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and drug-related supplies procured through competitive bidding and cooperative purchasing mechanisms. The issuing bodies soliciting under this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The scope of work reflects a mix of emergency response supplies (naloxone for opioid overdose), controlled drug deactivation systems for community health initiatives, generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers, and exploratory procurement for direct-to-manufacturer prescription programs to improve cost management and fulfillment efficiency.

Recent activity shows Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) with proposals due March 26, 2026 and contract effectiveness July 1, 2026; and the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capability information regarding direct-to-manufacturer prescription programs for self-insured state employee health plans. Geographic concentration appears in Florida and the Upper Midwest through the MMCAP cooperative (which spans multiple states including Oregon), with Texas representing exploratory procurement in the pharmaceutical benefits space.